Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 2, 2019--
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, on December 7-10, 2019.
The webcast will be accessible under “Events & Presentations” in the Investors & Media page of the company’s website at www.acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the “Acceleron ASH 2019 Conference Call.”
The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL ® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005177/en/
CONTACT: Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
Ed Joyce, 617-649-9242
Director, Investor Relations
Matt Fearer, 617-301-9557
Director, Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Acceleron Pharma
Copyright Business Wire 2019.
PUB: 12/02/2019 07:00 AM/DISC: 12/02/2019 07:01 AM